Definitive Contract 75A50124C00049
Award Date
9/25/24
Potential Completion Date
12/23/30
Potential Value
$135M
Awardee
Gigagen Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
PSC Category
Q701 - Specialized Medical Support
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
San Carlos, CA 94070, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award to Regeneron Pharmaceuticals Inc., a for-profit manufacturer of pharmaceuticals and therapeutics. The $692,086,314.00 award was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services (HHS). The contract is for the development and production of "novel antibodies against influenza virus, emerging, re-emerging, and pre-emerging pathogens" under an Other...
This federal contract award is for $17,568 to Genscript USA Inc., a biotechnology company in Piscataway, New Jersey. The contract is with the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS). The contract is for monoclonal antibodies and plasmids services to support biomedical research and public health initiatives. While the contract does not have a set-aside designation, Genscript has received other prime and...
The Department of Health and Human Services' Biomedical Advanced Research and Development Authority awarded a $269,952,453 firm fixed price definitive contract to Global Health Investment Corporation, a nonprofit organization. This contract establishes a public-private partnership through BARDA's other transaction authority to address gaps in pandemic preparedness and response. Specifically, the partnership will foster and accelerate medical countermeasure development using strategic venture...
This federal contract award is for a CUSTOMIZED POLYCLONAL ANTIBODY GENERATION SERVICE provided by Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract, valued at $14,932.80, was awarded on August 21, 2015 by the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS). The contract does not have a set-aside designation. Genscript has...
This federal contract award, valued at $330,136,246.14, was granted by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency within the U.S. Department of Health and Human Services, to 4J Therapeutics Inc., a self-certified small disadvantaged business. The contract's objective is to demonstrate the versatility and efficacy of 4J Therapeutics' programmable antiviral technology platform by assembling a preclinical package for LNA14, performing a Phase 1a...
This firm fixed-price purchase order, valued at $16,215, was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Genscript USA Inc., a biotechnology company based in Piscataway, New Jersey. The contract is for the provision of monoclonal antibodies and plasmids services to support NIAID's biomedical research and public health initiatives. Genscript, a for-profit organization, has received numerous prime...
This $38,199,745 federal contract was awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS) to Mapp Biopharmaceutical, Inc., a biotechnology company specializing in antibody-based therapeutics and medical countermeasures against infectious diseases and biothreats. The contract supports the development of medical countermeasures through planned clinical trials and outbreak preparedness. It is not set...
This is a federal contract award made by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Genscript USA Inc., a biotechnology company, for the procurement of antibodies and gene expression products to support COVID-19 research. The one-year contract has a firm fixed price of $111,122.25 and was awarded on June 23, 2020, with a completion date of June 22, 2021. The contract does not have a set-aside designation. Genscript has previously received...
This firm fixed price purchase order was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Geneimmune Biotechnology Corp., a biotechnology company based in Rockville, Maryland. The $31,435.00 contract is for the production of 20 liters of monoclonal antibodies at $1,500 per liter. This award supports NIAID's infectious disease research efforts, leveraging Geneimmune's expertise in areas such as gene...
This is a $65,806,649.98 cost-plus-fixed-fee contract awarded by the Office of the Assistant Secretary for Preparedness and Response, a civilian agency, to Biofactura Inc. for preclinical and manufacturing development activities. The contract includes cell line development, process development, non-clinical efficacy and safety studies, manufacturing, and clinical activities. The contract was awarded on September 26, 2019 with an ultimate completion date of March 30, 2029. The contract has no...